Co-administration of toll-like receptor (TLR)-3 agonist Poly I:C with different infectious bursal disease (IBD) vaccines improves IBD specific immune response in chicken

T. R. Kannaki1 · E. Priyanka1 · Manda Abhilash2 · Santosh Haunshi1

Received: 23 April 2021 / Accepted: 22 June 2021 / Published online: 7 July 2021 © The Author(s), under exclusive licence to Springer Nature B.V. 2021

Abstract
Toll-like receptor (TLR) agonists are emerging as promising vaccine adjuvants and immunomodulators in poultry against many diseases. Infectious bursa disease (IBD) still remains as a major threat to poultry industry. Improving the vaccine mediated immune response would help in better protection against IBD virus infection. Adjuvant potential of TLR3 agonist, Polinosinic polycytidylic acid (Poly I:C) with different IBD vaccines has been analyzed in chicken in the present study. Intermediate, intermediate plus IBD vaccine, bursaplex vaccine and their respective poly I:C combinations were used for immunization of chicken. IBD specific antibody titers, bursa to body weight ratio, body weight gain and bursal lesion scores were evaluated at weekly interval in different immunization groups. Fold changes in cytokines IL-1β and IFN-γ mRNA expression levels in spleen were also analyzed in different groups. Intermediate plus IBD vaccine induced significantly (P ≤ 0.05) higher IBD specific antibody response at 35 days of age than other groups with comparatively lower body weight gain and moderate bursal lesion score. Poly I:C co-administration with intermediate IBD vaccine and bursaplex vaccine improved the IBD specific antibody titers, better body weight gain and moderately less bursal lesion score. However, Poly I:C combination with intermediate plus IBD vaccine did not improve the specific immune response. IL-1β levels were up-regulated in intermediate plus and bursaplex group, whereas IFN-γ mRNA expression levels were upregulated in intermediate IBD with Poly I:C group. In conclusion, poly I:C co-administration with intermediate IBD and bursaplex vaccine was beneficial and improved the specific immune response with least immunosuppression and bursal damage.

Keywords IBD vaccines · Poly I:C · TLR3 agonist · Chicken

Introduction

TLR ligands or agonists are considered as promising adjuvant candidates due to their role in self/ non-self-differentiation, antigen presenting cell maturation and downstream cytokine stimulation (Janeway and Medzhitov 2002; Bendelac and Medzhitov 2002). Many TLR agonists including cytidine phosphate guanosine (CpG), flagellin, Polinosinic polycytidylic acid (Poly I:C) and S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine (Pam2CSK4) are currently being tested or employed along with many vaccines to improve immune response (Sayers et al. 2012). The potential of TLR ligands as adjuvants and prophylactic agents has also been established with many poultry vaccines (Bhadouriya et al. 2019).

Infectious bursal disease (IBD) is one of the most important viral disease of poultry caused by IBD virus (IBDV), a non-enveloped ds RNA virus of Birnaviridae family (Eterradossi 2020; Muller et al. 1979). IBDV targets the bursa of Fabricius of 3–6 weeks old chicks resulting in immunosuppression and mortality (Hirai and Shimakura 1974). Biosecurity and vaccination are two major effective strategies for IBD control. At present, live attenuated, killed and immune-complex IBD vaccines are available for effective control of IBD (Liew et al. 2016). Live attenuated IBD vaccines are mainly used in broilers at early stages for protection; although killed vaccines are employed in breeders for the induction of maternal
antibodies (MDA) and subsequent protection of chicks at early stages. Among the modified live IBV vaccines, intermediate and intermediate plus (hot) vaccines are widely used based on the disease incidences and maternal immunity levels. Although these vaccines are capable of inducing protective IBD specific immunity in host, immunosuppression due to bursal damage by the vaccine viruses is major drawback (Rautenschlein et al. 2007). Alleviating the immunosuppressive effect of IBD vaccines and potentiating their immunostimulation has more implications at field level.

Poly I:C, a dsRNA analogue, is a well characterized TLR3 agonists, induce type I IFNs in chickens and act as an antiviral agent (Karpala et al. 2008; Parvizi et al. 2012). Adjuvant effect of poly I:C have been demonstrated with inactivated avian influenza vaccine in chicken and ducks (Liang et al. 2013; Ichinohe et al. 2007; Zhang et al. 2017). Enhanced protection and reduced tumor development were observed in chicken immunized with HVT vaccine for Marek’s disease along with poly I:C (Parvizi et al. 2012). Earlier we reported the improvement Newcastle disease (ND) specific immune response in chicken upon co-administration of Poly I:C with mesogenic R2B live ND vaccine (Kannaki et al. 2019). However, there is dearth of information on the effect of Poly I:C and its adjuvant potential with IBD vaccines. In the present study, we explored the immunomodulatory potential of poly I:C with different types of IBD vaccines in chicken.

Materials and methods

Experimental birds

Day old Vanaraja chicks (n = 320) hatched from hatchery of ICAR-Directorate of Poultry Research, Hyderabad were used in the present study. Chicks were housed, fed with standard nutrition and provided ad libitum water. All the experiments were carried out following ethical guidelines and approved by Institute animal ethics committee (IAEC/DPR/2017/7). All the chicks received HVT vaccine for Marek’s disease at day-old and LaSota vaccine for ND at 5th and 28th day through intranasal route at recommended dose.

IBD vaccines and TLR3 agonist

Commercially available vaccines viz., intermediate, intermediate plus (Venky’s India Pvt. Ltd., India) and bursaplex (Zoetis India Pvt Ltd., India) IBD vaccines were procured and used. TLR3 agonist, Poly I:C (Sigma, MO, USA) dissolved in sterile nuclease free water was used in the study.

Table 1 Immunization plan to assess the immunomodulatory potential of Poly I:C with different IBD vaccines in chicken

| Groups       | Prime¹ | Poly I:C² (10 µg/ bird) | Booster³ |
|--------------|--------|------------------------|----------|
| I: Int IBD   | +      | –                      | +        |
| II: Int IBD plus | +   | –                      | +        |
| III: Bursaplex | +⁺    | –                      | –        |
| IV: Int IBD + Poly IC | +     | +                      | +        |
| V: Int IBD plus + Poly IC | +     | +                      | +        |
| VI: Bursaplex + Poly IC | +⁺ | +                      | –        |
| VII: Only Poly IC | +    | +                      | –        |
| VIII: Unimmunized control | –     | –                      | –        |

¹: Immunization at day-old by i/m route  
²: Poly I:C given by i/m route  
³: booster dose on 16th day of age

Immunization trial

One-day old vanaraja chicks were randomly divided into eight groups of 40 chicks each and immunized as follows. Bursaplex and poly I:C adjuvanted (10 µg/ chick) with bursaplex vaccine were given by subcutaneous route (s/c) at day old. Other vaccines viz., intermediate, intermediate plus IBV and poly I:C adjuvants of respective vaccines were given on 10th day of age and booster dose on 16th day of age. Intermediate and intermediate plus vaccine were given by oral route either alone or in combination with Poly I:C by intramuscular route (10 µg/ chick). Poly I:C control group received only Poly I:C by intramuscular route. Unimmunized control received only sterile PBS by i/m route (Table 1). All the vaccines were given at recommended dose as per the manufacturer’s instruction.

Evaluation of humoral immune response

Blood samples from different groups of immunization trial (n = 6 /each group) were collected at weekly interval from 7D and up to 35D (7, 14, 21, 28 and 35D), serum separated and stored at -20ºC until further analysis. IBD specific serum antibody response from serum samples were analyzed by indirect ELISA (IDEXX laboratories, USA) by following manufacturer’s instruction. Briefly, the test was performed on 96-well ELISA plate precoated with IBDV antigen. Diluted (1:500) test sera were dispended (100 µl/well) in duplicates. Undiluted positive and negative controls (each 100 µl/well) provided along with the kit were also dispended on the coated wells. After incubating for 30 min at 25ºC, the plates were washed with distilled water to remove any unbound material and followed by the addition of 100 µl

Table 1 Immunization plan to assess the immunomodulatory potential of Poly I:C with different IBD vaccines in chicken
conjugate. After 30 min at 25°C, the unbound conjugate was washed away and TMB substrate (100 µl) was added. The subsequent color developed was measured by spectrophotometer at 650 nm and corresponding OD values were recorded. The respective antibody titers were calculated as given below:

\[
Titer = \text{Antilog}\left[1.09\ (\log\ 10\ S/P)\right] + 3.36
\]

wherein \(S/P\) = [Mean OD of test sample-Mean OD of negative control] / [Mean OD of positive control-Mean OD of negative control].

The OD values were converted into titers using their software (xChekPlus, IDEXX). The titer greater than 396 is considered positive.

ND specific antibodies were also analyzed in the serum samples by haemagglutination inhibition (HI) test using 1% chicken RBCs, OIE protocol. The HI titer was determined as the highest dilution of serum samples that inhibited NDV agglutination of chicken RBCs.

**Body weight gain, Bura bodyweight ratio and bursal lesion scoring**

Body weight of three randomly selected birds from each group was recorded at weekly interval (7, 14, 21, 28, 35 & 42 D). The mean difference in body weight of different group birds (\(n = 3\)) at 7 D and 42 D was calculated as body weight gain during immunization trial. Three birds from each group were humanely sacrificed at weekly interval; bursa tissue was collected and weighed. Bursa to body weight ratio (B:BW) was calculated as: bursa of Fabricius weight (g) / Body weight (g) x 1000. Bursa tissue from different groups collected on 21st day was subjected to histopathological lesion scoring. The scoring was performed as per Muskett et al. (1979) using following scale: No damage (0); mild necrosis (1); moderate and generalized lymphoid depletion (2); severe lymphoid depletion (3); atrophy of follicles and fibroplasia (4).

**RNA extraction and cDNA synthesis**

Spleen tissue from different groups of experimental birds were collected aseptically after humane sacrifice at 14th day of age (\(n = 3\) /each group). Total RNA was extracted by using TRIzol (Invitrogen, CA) according to the manufacturer’s protocol and treated with DNase I (MBI Fermentas, USA) to remove traces of genomic DNA. The purity and concentration of extracted RNA were checked in Nanodrop™ -2000 spectrophotometer (Thermo Fisher Scientific, USA) Subsequently, 5 ng of purified RNA was reverse transcribed to cDNA using Superscript II first strand cDNA synthesis kit (Invitrogen, CA).

**Real time PCR quantification (qRT-PCR) of IL-1β and IFN-γ cytokine mRNA levels**

Cytokine mRNA expression levels of interleukon-1β (IL-1β) and IFN-γ were analyzed by real-time PCR using Maxima SYBR Green qPCR kit (MBI Fermentas, USA) in diluted cDNA samples using Insta Q96™ real time PCR machine (Himedia, India). The guidelines of Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) were followed. Primer amplification efficiency was assessed for each gene from the standard curve generated by using serial tenfold dilution of transcribed RNA. Regression analysis of the Ct values of standard curve was done to calculate slope and amplification efficiency of the primers. The efficiency for the primers ranged from 94 to 96%. For real time PCR, each 10 µl reaction mixture contained 5 µl of 2X Maxima SYBR Green PCR Master Mix, 1 µl of cDNA, and gene specific primers (20 pmol/µl) listed in Table 2. Briefly, each reaction involved a pre-incubation step at 94°C for 30 s, followed by 40 cycles of 95°C for 30 s, 55°C for 30 s and extension at 72°C for 30 s. Subsequently melting curve analysis was performed to check the specific product. Each sample was run in triplicate with no template control (NTC). β actin was used as housekeeping gene for normalizing the expression data.

**Statistical analysis**

Humoral immune response data including IBD and ND titers were analyzed by one-way analysis of variance (ANOVA) with Tukey’s post-hoc test to analyze the difference between mean titer between groups at different time intervals. Mean titers were considered significantly different when \(P \leq 0.05\). Statistical analysis was performed using SPSS v. 14. Body

| Gene   | Forward Primer (5’-3’) | Reverse Primer (5’-3’) | Amplicon size (bp) | Reference          |
|--------|------------------------|------------------------|--------------------|--------------------|
| IL-1β  | GGATTCTGAGCCACCCACACTG | TCTGGTTGATGTCCGAAGATGTC | 272                | Nang et al. (2011) |
| IFN-γ  | TGAGCCAGATGTTTTCGATG  | CTTGCGCAGGTCCATGATA   | 152                | Nang et al. (2011) |
| α-actin| CCGTAAGGACCTGTACGCAAAC | GCTGATCCACATCTGCTGAAAG | 208                | Fan et al. (2013)  |
weight gain, bursa to body weight ratio and bursal lesion scores were also analyzed by one-way ANOVA for any significant differences between groups. Expression levels of IL-1β and IFN-γ mRNA were calculated after normalizing with housekeeping gene and fold-changes in gene expressions were calculated as $2^{-\Delta\Delta Ct}$ (Livak and Schmittgen 2001). Comparison of fold changes in gene expression between groups were performed using General Linear Model in version 9.2 of SAS software with a P value < 0.05 considered significant.

Results

**IBD specific antibody titer**

Mean maternal antibody level of day-old chicks was 3800 ± 356. In poly I:C and unimmunized control group the maternal antibody levels declined and reached to unprotective (< 396) levels from 21st day of age (Fig. 1). However, the groups which received IBD vaccine either alone or in combination with Poly I:C induced seroconversion and protective antibody titers from 28-35th day (Protective titer cut-off: 396). Among the immunized groups, intermediate IBD plus vaccine induced significantly (Mean titer 3912 ± 1385; $P \leq 0.05$) higher levels of IBD specific antibodies on 35th day of age than other vaccine groups; followed by intermediate plus co-administered with poly I:C (1481 ± 914). Intermediate IBD vaccine, bursaplex vaccine and their combination with poly I:C also induced higher and protective antibody titers on 35th day of age. Poly I:C combination with intermediate and bursaplex vaccine induced better IBD specific antibody titers than the vaccine alone. However, for intermediate plus vaccine, poly I:C combination did not improve the titers.

**HI titer**

Significant differences ($P \leq 0.05$) in mean HI titer were observed between different groups on 4th and 5th week of age (Fig. 2). Intermediate IBD and intermediate plus vaccines in combination with Poly I:C groups showed significantly lower HI titers on both 4th and 5th week in comparison to other groups. Protective antibody titers were observed in all groups from 5th week onwards. Control group that did not receive any ND vaccine showed waning of ND antibody titer from 2nd to 3rd week and become unprotective for ND from 4th week onwards (data not shown).

**Body weight gain, Bursa to Body weight ratio and bursal lesion score**

Body weight gain calculated between the period of 7-days to 42 days of age during immunization trial showed significantly lower ($P \leq 0.05$) in intermediate plus IBD and Intermediate plus IBD with Poly I:C group in comparison to other groups and control (Fig. 3). Bursa to body weight ratio between different groups ranged from 1.72 to 4.96 (Table 3). No significantly difference was observed among the different groups on different intervals. Histopathological bursal lesion scoring for different groups on 21st day of age did not show any significant
**Fig. 2** ND HI (Log2) titer of different immunization groups at weekly interval. Bars marked with * differ significantly ($P < 0.05$); ($n=6$/group). Values are mean titers ± SEM.

**Fig. 3** Body weight gain in different immunization groups (between 7th day and 42nd day). Bars marked with * differ significantly ($n=3$/group). Body weight gain calculated as mean difference in weight (in g) between 7 and 42D of age.

| Table 3 | Bursa to body weight ratio (BB ratio*) of different immunization groups at weekly interval |
|----------|------------------------------------------------------------------------------------------|
| Groups   | 1st week | 2nd week | 3rd week | 4th week | 5th week |
| I: Int IBD  | 1.99 | 2.36 | 3.65 | 3.21 | 3.00 |
| II: Int IBD plus | 2.26 | 2.54 | 2.92 | 3.32 | 2.36 |
| III: Bursaplex | 2.13 | 2.73 | 2.45 | 2.37 | 1.79 |
| IV: Int IBD + Poly IC | 1.99 | 3.51 | 2.61 | 3.97 | 4.96 |
| V: Int IBD plus + Poly IC | 1.95 | 2.91 | 2.05 | 2.81 | 1.39 |
| VI: Bursaplex + Poly IC | 1.72 | 3.11 | 2.67 | 3.13 | 2.44 |
| VII: Only Poly IC | 2.11 | 2.55 | 3.71 | 2.75 | 3.13 |
| VIII: Unimmunized control | 2.17 | 3.27 | 4.12 | 3.46 | 2.50 |

$N=3$/group

*BB ratio calculated as (bursa weight/ body weight) X 1000
IBD is one of the re-emerging threats to poultry industry worldwide. IBD causes severe acute infections in young broilers leading to bursal atrophy, immunosuppression and mortality in the range of 30% and 60% in broilers and layers respectively (Eterradossi 2020). Although vaccines are available to combat the IBD infection, certain issues like maternal antibodies and induction of bursal damage by live vaccines exists. Poly I:C, a TLR3 agonist is a safe and effective adjuvant for improving vaccine induced immune response in birds and animals. Poly I:C binds with TLR3 and activates MyD88 independent pathway through TIR-domain containing adapter-inducing interferon-β (TRIF) and activating the downstream molecules IRF-3 and NF-κb and results in the production of type I IFN and inflammatory cytokines (Kawai and Akira 2010). Its immunomodulatory potential has been demonstrated with killed avian influenza vaccine, Marek’s vaccine and ND vaccine in chicken (Kannaki et al. 2019). Poly I:C alone or in combination with Pam3CSK4, a TLR3 and 2 agonists respectively, alleviated hot IBD vaccine induced immunosuppression in chicken (Bashir et al. 2019).

In the present study, we evaluated the effect of poly I:C upon co-administration with different IBD vaccines in chicken. Humoral antibodies play a major role in the protection of IBDV infection. Positive correlation exists between the IBD antibody titer and the protection (Nakamura et al. 1994). The experimental chicks had intermediate levels of maternal antibodies on day-old. Maternally derived antibodies (MDAs) usually start wane after first week and becomes unprotective from 2 to 3 weeks of age without any vaccines (Le Gros et al. 2009). We also observed waning of MDAs to unprotective levels around 3rd week in unimmunized control group and Poly I:C group. In the present study, all three vaccines namely intermediate, intermediate plus and bursaplex vaccine alone and in combination with Poly I:C induced seroconversion and protective IBD specific antibody titers at 35 days of age even in the presence of higher levels of maternal antibodies. Rebound of antibody titers were observed at 35 D of age, around two weeks after booster vaccination, which is generally observed with prime-boost live vaccines. It is in conformity with earlier studies, wherein the seroconversion was observed around 18 days post-vaccination (Wyeth and Chettle 1990; Bose et al. 2003). Among the vaccines studied, intermediate plus vaccine could induce significantly higher antibody levels than other vaccine groups, nevertheless with moderate bursal lesions and growth suppression indicated by lower body weight gain during the trial period. Body weight gain was significantly lower in intermediate plus vaccine group similar to earlier studies (Ashash et al. 2019).

All these vaccines are shown to induce protective antibody titers in the presence of maternal antibodies (MDA) (Sedeik et al. 2018). Immune-complex vaccine is a mixture of the intermediate plus strain and specific antibodies, that is released after MDA drops off. Moreover, these vaccines offer the practical advantage of hatchery administration as they are given at day-old by parenteral route (Haddad et al. 1997). Further, the recommended single dose avoids differences among the groups. However, the lesion score was slightly higher for intermediate plus and intermediate plus with Poly IC vaccine group numerically (Table 4).

### Cytokine mRNA expression levels

Fold changes in cytokines IL-1β and IFN-γ mRNA expression levels in spleen tissue of different groups on 14th day. Ct values are normalized with β-actin house keeping gene and fold changes are calculated with reference to unimmunized controls

| Groups            | Histopathological lesion scoring |
|-------------------|----------------------------------|
| I: Int IBD        | 1.5 ± 0.32                       |
| II: Int IBD plus  | 2 ± 0                            |
| III: Bursaplex    | 1.5                              |
| IV: Int IBD + Poly IC | 1.5 ± 0.75         |
| V: Int IBD + Poly IC | 2 ± 0                          |
| VI: Bursaplex + Poly IC | 1 ± 0.02                |
| VII: Only Poly IC | 0.75 ± 0.45                     |
| VIII: Unimmunized control | 0.75 ± 0.2               |

\(N = 3/\)group

Table 4: Histopathological bursal lesion scoring of different groups immunized with IBD vaccines and Poly I:C (Mean ± SEM)

### Table 5: Fold changes in cytokine IL-1β and IFN-γ mRNA expression levels in spleen by real time PCR in different immunization groups

| Groups            | IL-1 β | IFN-γ |
|-------------------|--------|-------|
| I: Int IBD        | 2.89   | 1.21  |
| II: Int IBD plus  | 4.24   | 1.80  |
| III: Bursaplex    | 4.21   | 3.20  |
| IV: Int IBD + Poly IC | 1.02   | 4.24  |
| V: Int IBD + Poly IC | 1.21   | 3.28  |
| VI: Bursaplex + Poly IC | 2.87   | 2.91  |

Age: 14th day. \(N = 3/\)group

Values are expressed as mean fold changes. Ct values are normalized with β-actin house keeping gene and fold changes are calculated with reference to unimmunized controls
handling of birds frequently as in conventional vaccines. We observed poly I:C co-administration improved the IBD specific immune response in intermediate and bursaplex IBD vaccine at 35 day of age, however, it is not the case in intermediate plus vaccine. Replication of vaccine virus in bursa and induction of bursal damages were directly correlated with their induction of humoral immunity (Rautenschlein et al. 2005). However, TLR agonist might reduce the replication of vaccine virus by upregulation of type I IFNs that are antiviral in nature (Cai et al. 2012). The effect may be more pronounced with hot vaccine compared to mild to moderate vaccines or immune complex vaccine that are slowly released. In an earlier study also, similar trend was observed and authors speculated the same (Bashir et al. 2019). Intermediate plus and intermediate IBD vaccines induce transient suppression of ND antibody titers (Rautenschlein et al. 2007). Transient suppression in ND titers was observed in the present study too around 35th day of age supporting the earlier notion. In vitro stimulation of chicken PBMCs and in vivo administration of poly I:C upregulated type I IFN transcripts (Karpala et al. 2008; Parvizi et al. 2012). Upregulation of IFN-γ was observed in spleen tissue of poly I:C immunized groups, however, it was not significantly different from IBD vaccine group. Upregulation of IFN-γ along with other genes IL-6, MHC-II and CD-4 were observed in spleen tissue of ducks immunized with H9N2 avian influenza inactivated vaccine adjuvanted with Poly I:C (Zhang et al. 2017). In addition, upregulation of IFN-γ was reported in chicken splenocytes stimulated with Poly I:C (Cornelissen et al. 2012).

In summary, poly I:C co-administration with different IBD vaccines showed that it improved specific immune response in intermediate IBD vaccine and bursaplex along with comparatively less immunosuppression and bursal damage. Hence, use of poly I: C along with these vaccinations would be beneficial to improve the vaccine response in broilers. Single injection of bursaplex with poly I:C is practically more useful for attaining better vaccine induced immunity.

Acknowledgements The authors sincerely thank the Director, ICAR-Directorate of Poultry Research, Hyderabad for providing necessary facilities for the research work.

Author’s contribution TRK- Conceived the experiment, designed, analyzed the data and prepared manuscript; EP & MA- conducted experiment, analyzed the samples; SH-Critically reviewed the manuscript.

Funding The research was funded by Indian Council of Agricultural Research and carried out at ICAR- Directorate of Poultry Research, Hyderabad, India.

Data availability Not applicable.

Code availability Not applicable.

Declarations All the experiments involving birds in the current study were carried out following the ethical guidelines and standards given by CPCSEA, India. The experiment was approved by institute animal ethics committee of ICAR-Directorate of Poultry Research (IAEC/DPR/2017/7).

Consent to participate Not applicable.

Consent for publication All authors have read and agreed to the published version of the manuscript.

Conflict of interest The authors declare that they have no conflict of interest.

References
Ashash U, Noach C, Perelman B, Costello C, Sansalbone P, Brazil T, Raviv Z (2019) In ovo and day of hatch application of a live infectious bursal disease virus vaccine to commercial broilers. Avian Dis 63(4):713–720
Bashir K, Kappala D, Singh Y (2019) Combination of TLR2 and TLR3 agonists derepress infectious bursal disease virus vaccine-induced immunosuppression in the chicken. Sci Rep 9:8197
Bendelac A, Medzhitov R (2002) Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 195:F19-23
Bhadoriya S, Sharma BK, Kakker NK, Chhabra R (2019) Toll like receptors and cytokines as immunostimulatory adjuvants in poultry vaccines: current status and future trends. Worlds Poult Sci J 75(3):417–428
Bose RK, Hossain KM, Sii BK, Taimur M, Pugliese C, Franci O (2003) Comparative sero evaluation of live and killed Gumboro vaccine in broilers. Ital J Anim Sci 2:157–162
Cai M, Zhu F, Shen P (2012) Expression and purification of chicken beta interferon and its antivirus immunological activity. Protein Expr Purif 84:123–129
Cornelissen JB, Post J, Peeters B, Vervelde L, Rebel JM (2012) Differential innate responses of chickens and ducks to low-pathogenic avian influenza. Avian Pathol 41(6):519–529
Ettaradossi YMS (2020) Infectious bursal disease. In: Swayne DE (ed) Diseases of poultry, 14th edn. Wiley Blackwell, New York, pp 257–283
Fan YF, Hou ZC, Yi GQ, Xu GY, Yang N (2013) The sodium channel gene family is specifically expressed in hen uterus and associated with eggshell quality traits. BMC Genet 14(1):90
Haddad EE, Whitfill CE, Avakian AP, Ricks CA, Andrews PD, Thoma JA, Wakenell PS (1997) Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis 41:882–889
Hirai K, Shimakura S (1974) Structure of infectious bursal disease virus. J Virol 14(4):957–964
Ichinohe T, Tamura SI, Kagawachi A, Ninomiya I, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H (2007) Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 196:1313–1320
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Ann Rev Immunol 20:197–216
Kannaki TR, Priyanka E, Reddy MR (2019) Co-administration of toll-like receptor (TLR)-3 and 4 ligands augments immune response to Newcastle disease virus (NDV) vaccine in chicken. Vet Res Commun 43:225–230
Karpala AJ, Lowenthal JW, Bean AG (2008) Activation of the TLR3 pathway regulates IFN beta production in chickens. Dev Comp Immunol 32(4):435–444
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384
Le Gros FX, Dancer A, Giacomini C, Pizzoni L, Bublot M, Graziani M, Prandini F (2009) Field efficacy trial of a novel HVT-IBD vector vaccine for 1-day-old broilers. Vaccine 27:592–596
Liang J, Fu J, Kang H, Lin J, Yu Q, Yang Q (2013) Comparison of 3 kinds of Toll-like receptor ligands for inactivated avian H5N1 influenza virus intranasal immunization in chicken. Poult Sci 92:2651–60
Liew P, Nurulfiza M, Omar A, Aini I, Hair-Bejo M (2016) Vaccines and vaccination against infectious bursal disease of chickens: Prospects and challenges. Pertanika J Schol Res Rev 2:23–39
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25(4):402–408
Muller H, Schltissek C, Becht H (1979) Genome of infectious bursal disease virus consisting of two segments of double-stranded RNA. J Virol 31:584–589
Muskett J, Hopkins I, Edwards K, Thornton D (1979) Comparison of two infectious bursal disease vaccine strains: efficacy and potential hazards in susceptible and maternally immune birds. Vet Rec 104(15):332–334
Nakamura T, Otaki Y, Lin Z, Nunoya T, Hoshi S, Kato A (1994) Direct correlation between the titer of infectious bursal disease virus VP2-specific antibody and protection. Avian Dis 2:251–255
Nang NT, Lee JS, Song BM, Kang YM, Kim HS, Seo SH (2011) Induction of inflammatory cytokines and toll-like receptors in chickens infected with avian H9N2 influenza virus. Vet Res 42(1):64
Parvizi P, Mallick AI, Haq K, Haghighi HR, Orouji S, Thantrigeddon N, St. Paul M, Brisbin JT, Read LR, Sharif Bebboudi S, S, (2012) A toll-like receptor 3 ligand enhances protective effects of vaccination against Marek’s disease virus and hinders tumor development in chickens. Viral Immunol 25:394–401
Rautenschlein S, Kraemer C, Vanmarcke J, Montiel E (2005) Protective efficacy of intermediate and intermediate plus infectious bursal disease virus (IBDV) vaccines against very virulent IBDV in commercial broilers. Avian Dis 49(2):231–237
Rautenschlein S, Kraemer C, Montiel E, Vanmarcke J, Haase C (2007) Bilateral effects of vaccination against infectious bursal disease and Newcastle disease in specific-pathogen-free layers and commercial broiler chickens. Avian Dis 51(1):14–20
Sayers S, Ulysse G, Xiang Z, He Y (2012) Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol 2012:831486
Sedeik ME, Awad AM, Rashed H, Elfeil WK (2018) Variations in pathogenicity and molecular characterization of Infectious Bursal Disease Virus (IBDV) In Egypt. Am J Anim Vet Sci 13(2):76–86
Wyeth PJ, Chettle N (1990) Use of infectious bursal disease vaccines in chicks with maternally derived antibodies. Vet Rec 126:577–578
Zhang A, Lai H, Xu J, HuangW Liu Y, Zhao D (2017) Evaluation of the protective efficacy of Poly I: C as an adjuvant for H9N2 subtype Avia Influenza inactivated vaccine and its mechanism of action in ducks. PLoS ONE 12(1):e0170681

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.